

Active substances set

Search phrase: irinotecan hydrochloride trihydrate

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant pancreatic cancer

Irinotecan hydrochloride trihydrate

Irinotecan hydrochloride trihydrate is indicated: - in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, - in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO